About the Company
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $INCY News
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
Incyte Corporation INCY is scheduled to release fourth-quarter and full-year 2023 results on Feb 13, before the opening bell. The company's earnings beat estimates in three of the trailing four ...
Incyte’s Hold Rating: Balancing Clinical Promise Against Financial and Market Position
JMP Securities analyst Reni Benjamin has reiterated their neutral stance on INCY stock, giving a Hold rating yesterday. Reni Benjamin has ...
Commit To Buy Incyte Corporation At $50, Earn 5.6% Annualized Using Options
Investors considering a purchase of Incyte Corporation (Symbol: INCY) stock, but cautious about paying the going market price of $58.03/share, might benefit from considering selling puts among the ...
Incyte, itching for a piece of Dupixent's market, hits goals in midphase skin disease trial
Regeneron and Sanofi tracked the effect of Dupixent on the itch scale in their phase 3 program. After 24 weeks, 60.0% and ...
Incyte Corporation (NASDAQ:INCY) Q4 2023 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY) Q4 2023 Earnings Call Transcript February 13, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.06 EPS, expectations were $1.21.
Incyte's JAK cream Opzelura proves its worth in treating hidradenitis suppurativa in midstage study
After a pair of approvals in recent years and as its sales continue to climb, Incyte's topical JAK inhibitor Opzelura is ...
5 Biotech Stocks with Huge Potential
Wilmington, Delaware-based Incyte Corporation (NASDAQ:INCY) is global biopharmaceutical company focused on the discovery, development, and commercialization of novel medicines across Oncology and ...
Incyte turns to generative AI to illustrate the 'unseen journey' of living with MPN
Generative artificial intelligence has gotten a bad rap for churning out artwork featuring extra limbs, otherworldly ...
Incyte Stock (NASDAQ:INCY), Quotes and News Summary
Vandana Singh MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation ...
Incyte Gets Phase II Win, Targets Blockbuster Dupixent in Skin Disease
Incyte’s povorcitinib met both primary and secondary endpoints to relieve itching and improve skin clearance by 16 weeks, ...
Loading the latest forecasts...